ESMO Events 2025

Meetings | ESMO

Welcome to our ESMO Virtual Congress site where we showcase the very best from ESMO's flagship portfolio.

• ESMO AI & Digital Oncology Congress 2025

• 17^th European Multidisciplinary Congress on Urological Cancer EMUC 2025 (Please see this article collection further down this page, at the end of the ESMO AI & DO Congress article collection)

ESMO AI & Digital Oncology Congress 2025

Serving as a central platform for the latest research, ethical discussions and technological advancements, the ESMO AI & Digital Oncology Congress fosters learning and collaboration among healthcare and digital health stakeholders.

A vital platform for experts from various fields to connect and for cancer healthcare practitioners to gain insights into AI & digital health breakthroughs, staying at the forefront of digital transformation in cancer care.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• ESMO guidance on the use of Large Language Models in Clinical Practice (ELCAP) E.Y.T. Wong, L. Verlingue, M. Aldea, M.A. Franzoi, R. Umeton, S. Halabi, N. Harbeck, A. Indini, A. Prelaj, E. Romano, E. Smyth, I.B. Tan, A. Valachis, J. Vibert, I.C. Wiest, Y.H. Yang, S. Gilbert, G. Kapetanakis, G. Pentheroudakis, M. Koopman, J.N. Kather

• Artificial intelligence entering the pathology arena in oncology: current applications and future perspectives A. Marra, S. Morganti, F. Pareja, G. Campanella, F. Bibeau, T. Fuchs, M. Loda, A. Parwani, A. Scarpa, J.S. Reis-Filho, G. Curigliano, C. Marchiò, J.N. Kather

ESMO Open

• The landscape of conventional and artificial intelligence-based clinical prediction models in non-small-cell lung cancer: from development to real-world validation H.R. Howard, M. Hasanova, A. Tiwari, A. Ghose, R. Winayak, T. Nahar, V. Chauhan, S. Arun, K. Palmer, A. Houston, N.S. Kumar, S. Lalwani, A. Januszewski, J. Conibear, A. Jain, A. Cortellini, A. Passaro, A. Addeo, V. Noronha, G.L. Banna, S. Boussios

• A radiomics-based artificial intelligence model to assess the risk of relapse in localized colon cancer C. Prieto-de-la-Lastra, J.A. Carbonell-Asins, A. Bueno, A. Gómez-Alderete, M. Busto, A.B. Alcolado-Jaramillo, A. Jimenez-Pastor, X. Monzonís, A. Cuñat, C. Montagut, P. Moreno-Ruiz, M. Huerta, D. Roda, F. Gimeno-Valiente, A. Estepa-Fernández, F. Bellvís-Bataller, A. Fuster-Matanzo, J. Gibert, S. Roselló, C. Martinez-Ciarpaglini, J. Vidal, Á. Alberich-Bayarri, A. Cervantes, N. Tarazona

Immuno-Oncology and Technology

• Integrated noninvasive diagnostics for prediction of survival in immunotherapy M. Yeghaian, Z. Bodalal, T.M. Tareco Bucho, I. Kurilova, C.U. Blank, E.F. Smit, M.S. van der Heijden, T.D.L. Nguyen-Kim, D. van den Broek, R.G.H. Beets-Tan, S. Trebeschi

• Deciphering the tumour immune microenvironment cell by cell M. Nabhan, D. Egan, M. Kreileder, V. Zhernovkov, E. Timosenko, T. Slidel, S. Dovedi, K. Glennon, D. Brennan, W. Kolch

ESMO Gastrointestinal Oncology

• Development of a novel routine blood-based AI model for HCC screening—a territory-wide study K.-N. Kwok, K.-M. Chueng, S.J.-L. Lam, M. Seo, C.Y. Lau, P.Y.-M. Woo, H.-S. Lam, S.-M. Yip, S. Lam, O.-P. Chiu, W.W.Y. Sung, H.H.-W. Liu, K.K.-H. Bao, J.C.-H. Chow, S.K.-K. Ng, H.H.-Y. Yiu, D.C.C. Lam

ESMO Real World Data and Digital Oncology

• Artificial intelligence-driven phase recognition in lung surgery: a single-centre pilot study☆ S.J.-Y. Ohtani-Kim, J. Samejima, M. Wakabayashi, M. Tada, T. Miyoshi, Y. Matsumura, K. Tane, K. Aokage, Y. Ishikawa, K. Hayashi, T. Ogane, K. Sasaki, S. Takenaka, Y. Kinebuchi, M. Ito, M. Tsuboi

• Integrating radiomics and real-world data to predict immune checkpoint inhibitor efficacy in advanced non-small-cell lung cancer☆ L. Provenzano, M. Favali, L. Mazzeo, A. Spagnoletti, M. Ruggirello, G. Calareso, F.G. Greco, R. Vigorito, A. Quarta, F. Calimeri, M. Monteleone, G. Baselli, E. De Momi, B. Guirges, A. Di Lello, A. Zec, A. Ferrarin, C. Giani, C. Silvestri, M. Occhipinti, M. Brambilla, R. Leporati, S. Manglaviti, C. Cavalli, G. Mazzoli, D. Miliziano, G. Di Liberti, B.M. Marino, S. Frasca, R. Di Mauro, A.D. Dumitrascu, T. Beninato, C. Proto, M. Ganzinelli, A. Vingiani, D. Lorenzini, C. Agosta, M. Borraccino, C. Bonalume, V. Bartolomeo, R. Romanò, P. Solli, A.R. Filippi, S. Sangaletti, M. Restelli, A. Marchianò, M.C. Garassino, F. de Braud, F. Trovò, A.L.G. Pedrocchi, G. Lo Russo, V. Miskovic, A. Prelaj

ESMO Rare Cancers

• The European Prospective Investigation into Cancer and Nutrition Cohort (EPIC): a gateway to rare cancer epidemiological research L. Fernandez-Cuesta, C. Voegele, B. Hemon, K. Alcala, D. Aune, S. Caini, E. Casalone, A.J. Cross, P. Ferrari, N. Girard, V. Katzke, R.S. van Leeuwaarde, G. Matullo, B. Melin, G. Murphy, V. Viallon, T. Walter, M.J. Gunter, A. Trama, N. Alcala, M. Foll

• A multi-omics analysis of transformed nodal marginal zone lymphoma J.A.A. Bult, Y. Zhong, F.A. de Groot, R.A.L. Groen, N. Veltmaat, D. Al-Sarayfi, A. Seitz, M. Mastik, E. Hilbrands, W.J. Plattel, J. Kluiver, A. van den Berg, S. Rosati, A. Diepstra, J.S.P. Vermaat, M. Nijland

ESMO affiliated journals

• Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study P. Barthelemy, A. Thiery-Vuillemin, T. Lebret, P. Bigot, U. Stein, L.M. Dourthe, R. Longo, P. Gimel, B. Auberger, J. De La Cruz, D. Malak, Z. Samia, N. Texier, L. Albiges

• Artificial intelligence as treatment support in breast cancer: current perspectives Stefan Lukac, Florian Putz, Giacomo De Micheli, Chiara Corti, Wolfgang Janni, Sara M. Tolaney, Giuseppe Curigliano, Sibylle Loibl, Paolo Tarantino, Jose Pablo Leone

• The importance of education and training in neuroendocrine neoplasms: challenges and opportunities for multidisciplinary management Francesco Panzuto, Simona Barbi, Annalisa Trama, Nicola Fazio

• Enhancing radiotherapy techniques for Triple-Negative breast cancer treatment Saharnaz Sarlak, Gilles Pagès, Frédéric Luciano

• Long-term outcomes from pembrolizumab monotherapy in patients with advanced NSCLC, PD-L1 expression ≥ 50 %, and poor performance status: Transformer-based AI to characterize prognostic complexity Alessio Cortellini, Edoardo Garbo, Giulia La Cava, Fabrizio Citarella, Valentina Santo, Leonardo Brunetti, David J Pinato, Jarushka Naidoo, Monica Loza, Carlo Genova, Scott Gettinger, So Yeon Kim, Ritujith Jayakrishnan, Talal El Zarif, Marco Russano, Federica Pecci, Alessandro Di Federico, Michele Montrone, Dwight H Owen, Diego Signorelli, Mingjia Li, Andrea Camerini, Balazs Halmos, Bruno Vincenzi, Giulio Metro, Sai Yendamuri, Francesco Grossi, Eleni Josephides, Bartłomiej Tomasik, Raffaele Giusti, Emilio Bria, Martin Sebastian, Maximilian Rost, Fabian Acker, Lorenza Landi, Francesca Mazzoni, Alessandro Morabito, Alessandro Leonetti, Luca Cantini, Giannis Mountzios, Sukumar Kalvapudi, David O’Reilly, Eleni Karapanagiotou, Isabelle Monnet, Javier Baena, Marianna Macerelli, Margarita Majem, Aida Piedra, Diego L Cortinovis, Giuseppe Tonini, Gabriele Minuti, Laura Mezquita, Teresa Gorria, Teresa Beninato, Giuseppe Lo Russo, Arsela PrelaJ, Andrea De Giglio, Federica Biello, Frank Aboubakar Nana, Anne-Marie C. Dingemans, Joachim GJV Aerts, Roberto Ferrara, Taher Abu Hejleh, Kazuki Takada, Abdul R Naqash, Marina C Garassino, Heather A. Wakelee, Amin Nassar, Biagio Ricciuti, Paolo Soda, Camillo Maria Caruso, Valerio Guarrasi

• Artificial intelligence in predicting EGFR mutations from whole slide images in lung Cancer: A systematic review and Meta-Analysis Mai Hanh Nguyen, Minh Huu Nhat Le, Anh Tuan Bui, Nguyen Quoc Khanh Le

• Proposed Modifications to Prognostic Classification of AML Patients Treated with Intensive Chemotherapy Based on Recent Real-World Data Joseph Brandwein, David Page, Elena Liew, Jennifer Croden, Peng Wang

• Artificial Intelligence Assessment of Chest Radiographs for COVID-19 Koji Sasaki, Guillermo Garcia-Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda, Nitin Jain, Koichi Takahashi, Guillermo Montalban-Bravo, Naval G. Daver, Philip A. Thompson, Naveen Pemmaraju, Dimitrios P. Kontoyiannis, Junya Sato, Sam Karimaghaei, Kelly A. Soltysiak, Issam I. Raad, Hagop M. Kantarjian, Brett W. Carter, D3CODE Research Team

17th European Multidisciplinary Congress on Urological Cancer EMUC 2025

Top experts in medical oncology, pathology, radiation oncology, radiology, nuclear medicine, and urology gather at the congress to offer their special insights on best practices, developments in major trials, and breakthroughs.

Receive essential GU cancers updates, engage in popular hands-on training courses, and join eye-opening multidisciplinary case discussions.

Below a collection of papers recently published in ESMO’s premier journals carefully selected to reflect the themes of the meeting.

Annals of Oncology

• Final overall survival and safety analyses of the phase III PSMAfore trial of [177Lu]Lu-PSMA-617 versus change of androgen receptor pathway inhibitor in taxane-naive patients with metastatic castration-resistant prostate cancer K. Fizazi, K.N. Chi, N.D. Shore, K. Herrmann, J.S. de Bono, D. Castellano, J.M. Piulats, A. Fléchon, X.X. Wei, H. Mahammedi, G. Roubaud, M. Fleming, T. Haas, S. Ghebremariam, T.N. Kreisl, S. Rajagopalan, O. Sartor, M.J. Morris, for the PSMAfore Investigators

• Fracture-related hospitalisations in newly diagnosed high-risk localised or metastatic hormone-sensitive prostate cancer: secondary analysis of the STAMPEDE phase III trials of docetaxel and zoledronic acid using healthcare systems data C. Jones, P. Dutey-Magni, L.R. Murphy, M.L. Murray, J.E. Brown, E. McCloskey, M. Brown, C.L. Amos, D.C. Gilbert, R.J. Jones, W. Cross, D. Matheson, R. Millman, M.K.B. Parmar, G. Attard, M.R. Sydes, L.C. Brown, N.D. James, N.W. Clarke, A. Sachdeva, STAMPEDE Trial Investigators

ESMO Open

• Venous thromboembolic event risk with PARP inhibitors in solid tumors: a systematic review and meta-analysis S.C. Yazgan, E. Yekedüz, E. Akkuş, M. Sun, S. Gillessen, K. Fizazi, R.R. McKay, C. Ay, E. Castro, N. Agarwal, T.K. Choueiri, Y. Ürün

• Early detection, clinicopathological subtyping, and prognosis prediction for endometrial cancer patients using fragmentomics liquid biopsy assay Q. Rao, H. Zhou, W. Weng, . He, N. Li, P. He, W. Tang, M. He, X. Zhu, D. Zhu, H. Bao, X. Wu, H. Wang, Z. Lin, B. Zhang

Immuno-Oncology and Technology

• Region of interest localization, tissue storage time, and antibody binding density—a technical note on the GeoMx® Digital Spatial Profiler S. Böning, F. Schneider, A.-K. Huber, D. Langhoff, H. Lin, A. Kaczorowski, A. Stenzinger, M. Hohenfellner, S. Duensing, A. Duensing

• Potentiating intratumoral therapy with immune checkpoint inhibitors: shifting the paradigm of multimodality therapeutics B.E. Nelson, A. Naing, S. Fu, R.A. Sheth, R. Murthy, S. Piha-Paul

ESMO Real World Data and Digital Oncology

• Feasibility of Wave Health to monitor electronic patient-reported outcomes (ePROs) in prostate cancer patients B. Gomez Mediavilla, B. Congregado, E. Linares Espinos, I. Rivero Belenchon, L. Basterretxea, G. Sancho, N. Lainez, D. Buchser, T. Leturgez, A.A. Schmitz, J. Pozueta, I. Gurruchaga, D. Cacho Lavin, B. Esteban, A. Hernandez, M. Lashey, F. Sanguedolce, I. Duran

• Real-word evidence in anti-VEGF naive patients treated with pazopanib for metastatic renal cell carcinoma (mRCC), the APOLON Study P. Barthelemy, A. Thiery-Vuillemin, T. Lebret, P. Bigot, U. Stein, L.M. Dourthe, R. Longo, P. Gimel, B. Auberger, J. De La Cruz, D. Malak, Z. Samia, N. Texier, L. Albiges

ESMO affiliated journals

• Advances in treatment strategies for low-grade serous ovarian cancer

  Lucia Musacchio, Domenica Lorusso, Giulia Sabetta, Alessandra Giustozzi, Elena Giudice, Maria Chiara Cannizzaro, Maria Teresa Perri, Anna Fagotti, Vanda Salutari

• Impact of brain metastases on systemic renal cell carcinoma treatment outcomes: A systematic literature review

  Natalie Charnley, Kate Fife, Daniel Y.C. Heng, James Larkin, John McGrane, Sylvie Négrier, Naveen Vasudev, Balaji Venugopal, Alison Chisholm, Alessia Ogareva, Áine Prendergast, Laurence Albiges

ESMO's Journal Portfolio

While diverse in nature and in content, these journals offer ESMO members and the oncology community a highly visible platform to publish important scientific studies, and a highly credible source for educational updates. Elsevier is the proud publisher of Annals of Oncology, Immuno-Oncology and Technology (IOTECH), ESMO Open, ESMO Gastrointestinal Oncology, ESMO Real World Data and Digital Oncology, ESMO Rare Cancers, and ESMO Affiliated Journals The Breast, Lung Cancer, Cancer Treatment Reviews and Clinical Lymphoma Myeloma and Leukemia.